Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Suzhou's Innovent Strikes $457 Million Deal with CAS for Immuno-Oncology Candidate

publication date: Sep 7, 2017

Innovent Biologics of Suzhou announced a $457 million deal to acquire global rights for a small-molecule IDO inhibitor, which it intends to pair with its PD-1 candidate, IBI308. Both molecules are immuno-therapies, but their mechanisms are different. Innovent made the deal with the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. The agreement specifies an upfront payment plus milestones and a royalty, though details were not disclosed. In 2015, Lilly agreed to a $1 billion deal for ex-China rights to as many as nine Innovent biologic candidates; IBI308 is one of them. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.